Efektifitas Penggunaan Enoxaparin dan Fondaparinux Sebagai Antikoagulan Pada Pasien Covid-19 di RSUD Sidoarjo
Novianti Fatli Azizah(1*), Renny Nurul Faizah(2), Digna primasanti(3), Ikrimatul Khuluqiyah Prihantini(4), Imanda Gita Romadhian(5)
(1) Rumah Sakit Umum Daerah Sidoarjo
(2) Rumah Sakit Umum Daerah Sidoarjo
(3) Rumah Sakit Umum Daerah Sidoarjo
(4) Rumah Sakit Umum Daerah Sidoarjo
(5) Rumah Sakit Umum Daerah Sidoarjo
(*) Corresponding Author
Abstract
Keywords
Full Text:
PDFReferences
Albania, F., Sepea, L., and Fusinaa, F., 2020. Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. EClinicalMedicine, 27.
Cai, H., 2020. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. Vol 8, April 2020.
Gonagle, D.M., Sharif, K., Regan, A.O., and Bridgewood, C., 2020. The Role of Cytokine Including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Actifation Syndrom Like Diseases. Autoimmunity Reviews, Vol 19, Issues 6.
Klok, F.A., Kruipb, M.J.H.A., VanderMeer, N.J.M., Arbousd, M.S., Gommerse, D.A.M.P.J., Kant, K.M., Kapteina, F.H.J., Paassend, J.V., Stalsa, M.A.M., Huismana, M.V., and Endemane, H., 2020. Incidence of thrombotic complications in critically ill ICU patients with, Thrombosis Research, 145–147.
Kumar, A., Talwar, A., and Farley, J.F., 2019. Fondaparinux sodium compared with low molecular-weight heparins for Perioperative surgical thromboprophylaxis: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8:e012184.
Nadar, S.K., Goyal, D., Shantsila, E., Banerjee, P., and Lip, G.Y.H., 2009. Fondaparinux : an overview. Expert Rev. Cardiovasc. Ther. 7(6), 577–585.
Nasiri, M.J., Haddadi, S., Tahvildari, A., Farsi, Y., Arbabi, M., Hasanzadeh, S., Jamshidi, P., Murthi, M., and Mirsaeidi, M., 2020. Covid-19 Clinical Characteristic, and SexSpecific Risk of Mortality : Systemic Review and Meta-Analysis. Front. Med., Vol. 7, No. 459, pp. 1-10.
Oudkerk, M., Buller, H.R., Kuijpers, D., Es, N., Oudkerk, S.F., McLoud, T.C., Gommers, D., Dissel, J., Cate, H., and Beek, E.J., 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19. Report of the National Institute for Public Health of the Netherlands.
PDPI, PERKI, PAPDI, PERDATIN, IDAI, 2020. Pedoman Tatalaksana Covid-19, Edisi 2, ISBN: 978-623-92964-8-3, Jakarta, 56-64.
Rachmi, D.A., Mulia, E.P.B.M., and Nugroho, J., 2020. Possible Mechanism and Current Recommendation of Thromboembolism in COVID-19. J Med Sci. 2020 Jun 15; 8(T1):66-74.
Russo, V., Cardillo, G., Viggiano, G.V., Mangiacapra, S., Cavalli, A., Fontanella, A., Agrusta, F., Bellizzi, A., Amitrano, M., Iannuzzo, M., Sacco, C., Lodigiani, C., and DiMicco, P., 2020. Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. J Cardiovasc Pharmacol : Volume 76, Number 4
Scarvelis, D., and Wells, P.S., 2006. Diagnosis and treatment of deep-vein trombosis. Canadian Medical Association Journal. 2006 October 24, 2006:1087-92
Shah, S., Shah, K., and Patel, S.B., 2020. Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: A systematic review and meta-analysis. medRxiv. 04.29.20085407.
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., and Sun, Z., 2020. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J ThrombHaemost, 18(5):1094–9.
Turpie, A.G.G., 2006. Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vascular Health and Risk Management 2006:2(4) 371–378.
DOI: https://doi.org/10.22146/farmaseutik.v18i1.71913
Article Metrics
Abstract views : 4022 | views : 12005Refbacks
- There are currently no refbacks.